Search research articles
Contact Us
Filters
Showing results (131-140 of 327) with videos related to
Page
of 33
Sort By:
Cancer Treatment Reports
|
October 1, 1987
Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy
J H Schiller, B Storer, J K Willson, et al.
The Journal of General Virology
|
November 1, 1971
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies
F A Murphy, E C Borden, R E Shope, et al.
Infection and Immunity
|
March 1, 1971
Effect of antilymphocyte serium on tacaribe virus infection in infant mice
E C Borden, F A Murphy, N Nathanson, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1991
Interferon type I and II antagonism: a novel regulatory mechanism of indoleamine dioxygenase induction in human peripheral blood monocytes and peritoneal macrophages
Y Ozaki, E C Borden, R V Smalley, et al.
Current Urology
|
June 12, 2014
Prevalence of circulating tumor cells in localized prostate cancer
Kiranpreet K Khurana, Ronald Grane, Ernest C Borden, et al.
Cancer Research
|
August 1, 1986
Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors
Y A Sidky, E C Borden, W Wierenga, et al.
Cancer Treatment Reports
|
May 1, 1987
Phase II trial of acivicin in malignant mesothelioma
G Falkson, D A Vorobiof, I W Simson, et al.
British Journal of Cancer
|
March 3, 2011
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
V Cheriyath, M A Kuhns, M E Kalaycio, et al.
Cancer Research
|
January 1, 1985
Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide
E C Borden, Y A Sidky, D S Groveman, et al.
The Journal of Clinical Investigation
|
June 1, 1985
Low doses of interferon alpha result in more effective clinical natural killer cell activation
B S Edwards, J A Merritt, R C Fuhlbrigge, et al.
Page
of 33
Search research articles
Search
Showing results (131-140 of 327) with videos related to
Sort By:
Page
of 33
Cancer Treatment Reports
|
October 1, 1987
Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy
J H Schiller, B Storer, J K Willson, et al.
The Journal of General Virology
|
November 1, 1971
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies
F A Murphy, E C Borden, R E Shope, et al.
Infection and Immunity
|
March 1, 1971
Effect of antilymphocyte serium on tacaribe virus infection in infant mice
E C Borden, F A Murphy, N Nathanson, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1991
Interferon type I and II antagonism: a novel regulatory mechanism of indoleamine dioxygenase induction in human peripheral blood monocytes and peritoneal macrophages
Y Ozaki, E C Borden, R V Smalley, et al.
Current Urology
|
June 12, 2014
Prevalence of circulating tumor cells in localized prostate cancer
Kiranpreet K Khurana, Ronald Grane, Ernest C Borden, et al.
Cancer Research
|
August 1, 1986
Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors
Y A Sidky, E C Borden, W Wierenga, et al.
Cancer Treatment Reports
|
May 1, 1987
Phase II trial of acivicin in malignant mesothelioma
G Falkson, D A Vorobiof, I W Simson, et al.
British Journal of Cancer
|
March 3, 2011
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
V Cheriyath, M A Kuhns, M E Kalaycio, et al.
Cancer Research
|
January 1, 1985
Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide
E C Borden, Y A Sidky, D S Groveman, et al.
The Journal of Clinical Investigation
|
June 1, 1985
Low doses of interferon alpha result in more effective clinical natural killer cell activation
B S Edwards, J A Merritt, R C Fuhlbrigge, et al.
Page
of 33